This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Outcomes assessed in the review
The outcomes assessed from the literature were:
data on disease progression, which were based on the characteristics of a cohort of PD patients (i.e. age at onset, age at PD diagnosis, age at time of last visit, PD duration at first neurological assessment, PD duration at time of last visit, and proportions of patients in different HY stages at both the first and most recent visits); survival;
increased PD mortality in comparison with the general population; the health state utilities according to HY stage; the effectiveness of a future cell-based therapy for PD; and the frequency of complications such as haematoma and dyskinesias.
Study designs and other criteria for inclusion in the review
Since no details on the methods and conduct of a systematic review of the literature were provided, the primary studies might have been identified selectively. Data on disease progression came from a cohort of 79 PD patients (48 men, 31 women) randomised from the Department of Neurology of the Lund University Hospital in Sweden. In particular, the change in HY between the first and most recent visits in this cohort of patients was used to estimate disease progression, which also depended on HY Stage and age at PD diagnosis. Survival was derived from Swedish life tables. The utilities were estimated using the generic EuroQol (EQ-5D) scale, based on the time trade-off approach. Treatment effectiveness came from a study that involved a series of 14 patients (12 men, 2 women) with idiopathic PD who had received intrastriatal grafts of dopamine-rich human embryonic ventral mesencephalic tissue. The rate of complications was retrieved from a published review.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Seven primary studies provided the clinical data.
Methods of combining primary studies
The primary estimates appear to have been combined through a narrative approach.
Investigation of differences between primary studies
Not reported. No patient in the cohort died during the study follow-up.
Results of the review
The increased PD mortality in comparison with the general population was 1.8 for patients younger than 64 years and 1.5 for those aged 64 and older. The frequency of haematoma was 5% and that of dyskinesias 15%.
Measure of benefits used in the economic analysis
The summary benefit measure used was the cumulative number of quality-adjusted life-years (QALYs). These were estimated by combining the expected adjusted survival with utility weights in the decision model. Both series of data were derived from the literature. The benefits were discounted at an annual rate of 3%.
Direct costs
The authors did not explicitly state the perspective adopted in the study but the analysis included the direct costs associated with inpatient care, outpatient care, pharmaceuticals, investigations, transport and home help. The intervention costs (transplantation) covered procedural costs and the costs of haematoma and dyskinesias. The unit costs and the quantities of resources used were not presented separately. However, the costs were stratified by HY stage and by age (less or more than 64 years). All costs associated with the treatment of PD were derived from a published study. The costs and resource consumption of novel treatments were derived from clinical trials and other studies, and some assumptions were also made. Discounting was relevant, as the long-term costs were evaluated, and an annual rate of 3% was used. The price year was 2002.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs were not considered. Currency Swedish kroner (SEK). These were presented in euros (EUR). The exchange rate was SEK 9.19 = EUR 1.00.
Sensitivity analysis
A univariate sensitivity analysis was carried out to assess the robustness of the cost-utility ratios to variations in the time horizon (10, 20 and 30 years), discount rate (0 to 5%), treatment efficacy (+/-50%), occurrence of haematoma and dyskinesias (+/-100%), the inclusion of medical costs only, and the utility weights (derived using the visual analogue scale method). Alternative values were mainly based on authors' opinions. A threshold analysis was also performed to determine the price premium (profit or compensation for intervention developmental costs).
Estimated benefits used in the economic analysis
During a 25-year time horizon, the cumulative QALYs for patients who were preoperative HY Stage III were 2.880 in the control group and 3.753 in the intervention group (difference 0.873).
For patients who were preoperative HY Stage IV, the cumulative QALYs were 2.183 in the control group and 3.316 in the intervention group (difference 1.133).
Cost results
During a 25-year time horizon, the expected costs for patients who were preoperative HY Stage III were EUR 158,943 in the control group and EUR 156,467 in the intervention group (difference -EUR 2,476).
For patients who were preoperative HY Stage IV, the expected costs were EUR 186,279 in the control group and EUR 163,558 in the intervention group (difference -EUR 22,721).
Thus, the intervention costs were more than offset by a reduction in other direct costs, mostly related to home help.
Synthesis of costs and benefits
The costs and benefits were combined by calculating incremental cost-utility ratios. However, in the base-case analysis, the novel intervention for PD dominated usual care, which was both less effective and more expensive.
The authors also used two commonly used thresholds (EUR 38,000 and EUR 70,000 per QALY) to assess the size premium for intervention developmental costs. The analysis showed that the maximum price premium to remain costeffective ranged from EUR 12,000 to EUR 64,000 according to thresholds of EUR 38,000 to EUR 70,000 and depending on whether all costs, or only medical direct costs, were included in the analysis.
The sensitivity analysis showed that the base-case results were sensitive to variations in the time horizon (the intervention was less cost-effective with shorter the time horizons), treatment effect, and the method used to derive utility weights in the cohort of HY Stage III patients. The results were more stable for HY Stage IV patients. However, the intervention remained cost-saving or cost-effective for most variations in model parameters. The incremental cost per QALY for the intervention over control was higher than EUR 50,000 in only three cases. Specifically, with a timehorizon of 10 years for HY Stage III patients (EUR 66, 192 per QALY) , with a reduction of 50% in treatment effect for HY Stage IV patients (EUR 69,870 per QALY), and using the visual analogue scale to elicit preferences for HY Stage III patients (EUR 92,216).
Authors' conclusions
A novel therapeutic approach for Parkinson's disease (PD), such as dopamine cell replacement therapy, could be costeffective in the Swedish health care system. There could be room for a price premium in Hoehn and Yahr (HY) Stage III-IV patients with early onset PD.
